 | Up a level |
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
Sternberg, Cora N; Skoneczna, Iwona; Kerst, J Martijn; Albers, Peter; Fossa, Sophie D; Agerbaek, Mads; Dumez, Herlinde; de Santis, Maria; Théodore, Christine; Leahy, Michael G; Chester, John D; Verbaeys, Antony; Daugaard, Gedske; Wood, Lori; Witjes, J Alfred; de Wit, Ronald; Geoffrois, Lionel; Sengelov, Lisa; Thalmann, George; Charpentier, Danielle; ... (2015). Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. The lancet oncology, 16(1), pp. 76-86. Elsevier 10.1016/S1470-2045(14)71160-X
